Epidemiology and Pathophysiology of Epilepsy

2021 ◽  
pp. 719-721
Author(s):  
David B. Burkholder

About 10% of people in the United States have 1 seizure in their lifetime; less than 4% have recurrent seizures or epilepsy. Currently, more than 3.4 million people in the United States have active epilepsy, making it one of the most common neurologic disorders. Seizures can develop at any age, but the most common times are during childhood and after age 60 years. The greatest incidence is in elderly patients. Acute symptomatic seizures (also called provoked seizures or reactive seizures) result from new and active insults to the central nervous system.

1943 ◽  
Vol 89 (374) ◽  
pp. 42-51 ◽  
Author(s):  
Donald Blair

In March, 1939. there was admitted under my care at the St. Pancras Hospital Mental Observation Unit a case of torulosis of the nervous system. This is a very rare disease in this country and the present case is only the third recorded in British medical history (Greenfieldet al., 1938; Smith and Crawford, 1930), and the first one to have come under mental hospital supervision. Although such a rarity here, torulosis is more common in the United States, and cases have been reported from nearly every part of the world.


2019 ◽  
Vol 143 (2) ◽  
pp. 251-260 ◽  
Author(s):  
Haley Gittleman ◽  
Gino Cioffi ◽  
Toni Vecchione-Koval ◽  
Quinn T. Ostrom ◽  
Carol Kruchko ◽  
...  

PEDIATRICS ◽  
1962 ◽  
Vol 30 (4) ◽  
pp. 654-659
Author(s):  
Helen B. Taussig

THALIDOMIDE [alpha (N-phthalimido) glutarimide] is a synthetic drug with the structural formula shown in Figure 1. Thalidomide was invented by the firm of Chemie Grünenthal as a sedative, but when tested on animals was found to be ineffective. Chemie Grünenthal was, however, so certain that thalidomide must have some quieting effect on the central nervous system that it was then tested on man for its effect on epilepsy, and promptly reported to be useless as an anti-convulsant but an excellent sedative. By 1957, thalidomide, marketed under the trade-name of Contergan, was widely used as a sedative and for mental patients. It was considered "safe" to keep in the home because an overdose caused a sound sleep but never produced fatal poisoning. Thalidomide was added to other preparations for conditions where sedation would be beneficial, such as headaches (Algosedive, which is aspirin, phenacetin, and thalidomine), migraine, cough, asthma, gastrointestinal disturbances, grippe, arthralgia, and arthritis. A preparation with a small amount of thalidomide was sold as a tranquilizer. The rights to market the drug were sold to a number of foreign pharmaceutical firms, and the drug was exported to many other countries. Thus, to my certain knowledge, more than a dozen preparations have been placed on the market in a minimum of 16 countries, excluding the United States, where it was distributed to over 1,000 physicians for investigation. Table I gives a list of these drugs which the author has been able to check. Evidence is steadily accumulating which indicates that both the number of preparations and the number of countries is far in excess of the above figures.


Author(s):  
Morgan LR ◽  
Weiner RS ◽  
Ware ML ◽  
Bhandari M ◽  
Mahmood T ◽  
...  

In 2020 about 89,000 adolescents and young adults (AYA) (ages 15 to 39) were estimated to be diagnosed with cancer in the United States, 23,890 had CNS and spinal nervous system(SNS) involvement—accounting for one twentieth or five percent of the number cancer diagnoses in the United States. The estimated deaths for this group was18,020 deaths in 2020 (1).


Author(s):  
EV Walker ◽  
F Davis ◽  

The Canadian Brain Tumour Registry (CBTR) project was established in 2016 with the aim of enhancing infrastructure for surveillance and clinical research to improve health outcomes for brain tumour patients in Canada. We present a national surveillance report on malignant primary brain and central nervous system (CNS) tumours diagnosed in the Canadian population from 2009-2013. Patients were identified through the Canadian Cancer Registry (CCR); an administrative dataset that includes cancer incidence data from all provinces/territories in Canada. Cancer diagnoses are coded using the ICD-O3 system. Tumour types were classified by site and histology using The Central Brain Tumour Registry of the United States definitions. Incidence rates (IR) and 95% confidence intervals (CI) were calculated per 100,000 person-years and standardized to the 2011 census population age-distribution. Overall, 12,115 malignant brain and CNS tumours were diagnosed in the Canadian population from 2009-2013 (IR:8.43;95%CI:8.28,8.58). Of these, 6,845 were diagnosed in males (IR:9.72;95%CI:9.49,9.95) and 5,270 in females (IR:7.20;95%CI:7.00,7.39). The most common histology overall was glioblastoma (IR:4.06;95%CI:3.95,4.16). Among those aged 0-19 years, 1,130 malignant brain and CNS tumours were diagnosed from 2009-2013 (IR:3.36;95%CI:3.16,3.56). Of these, 625 were diagnosed in males (IR:3.32;95%CI:3.34,3.92) and 505 in females (IR:3.08;95%CI:2.81,3.36). The most common histology among the paediatric population was pilocytic astrocytoma (IR:0.73;95%CI:0.64,0.83). The presentation will include: IRs for other histologies, the geographic distribution of cases and a comparison between Canada and the United States.


Nanoscale ◽  
2017 ◽  
Vol 9 (42) ◽  
pp. 16281-16292 ◽  
Author(s):  
Tzu-Wei Wang ◽  
Kai-Chieh Chang ◽  
Liang-Hsin Chen ◽  
Shih-Yung Liao ◽  
Chia-Wei Yeh ◽  
...  

Functionalised self-assembling nanopeptide hydrogel mediates angiogenesis and neurogenesis for injured brain tissue regeneration.


2017 ◽  
Vol 19 (suppl_5) ◽  
pp. v1-v88 ◽  
Author(s):  
Quinn T Ostrom ◽  
Haley Gittleman ◽  
Peter Liao ◽  
Toni Vecchione-Koval ◽  
Yingli Wolinsky ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document